BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2151 related articles for article (PubMed ID: 25633049)

  • 1. MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer.
    Vilquin P; Donini CF; Villedieu M; Grisard E; Corbo L; Bachelot T; Vendrell JA; Cohen PA
    Breast Cancer Res; 2015 Jan; 17(1):13. PubMed ID: 25633049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular characterization of anastrozole resistance in breast cancer: pivotal role of the Akt/mTOR pathway in the emergence of de novo or acquired resistance and importance of combining the allosteric Akt inhibitor MK-2206 with an aromatase inhibitor.
    Vilquin P; Villedieu M; Grisard E; Ben Larbi S; Ghayad SE; Heudel PE; Bachelot T; Corbo L; Treilleux I; Vendrell JA; Cohen PA
    Int J Cancer; 2013 Oct; 133(7):1589-602. PubMed ID: 23553037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonhypoxic regulation and role of hypoxia-inducible factor 1 in aromatase inhibitor resistant breast cancer.
    Kazi AA; Gilani RA; Schech AJ; Chumsri S; Sabnis G; Shah P; Goloubeva O; Kronsberg S; Brodie AH
    Breast Cancer Res; 2014 Jan; 16(1):R15. PubMed ID: 24472707
    [TBL] [Abstract][Full Text] [Related]  

  • 4. miR-155 Drives Metabolic Reprogramming of ER+ Breast Cancer Cells Following Long-Term Estrogen Deprivation and Predicts Clinical Response to Aromatase Inhibitors.
    Bacci M; Giannoni E; Fearns A; Ribas R; Gao Q; Taddei ML; Pintus G; Dowsett M; Isacke CM; Martin LA; Chiarugi P; Morandi A
    Cancer Res; 2016 Mar; 76(6):1615-26. PubMed ID: 26795347
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Down-regulation of programmed cell death 4 (PDCD4) is associated with aromatase inhibitor resistance and a poor prognosis in estrogen receptor-positive breast cancer.
    Chen Z; Yuan YC; Wang Y; Liu Z; Chan HJ; Chen S
    Breast Cancer Res Treat; 2015 Jul; 152(1):29-39. PubMed ID: 26026468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane.
    Hole S; Pedersen AM; Hansen SK; Lundqvist J; Yde CW; Lykkesfeldt AE
    Int J Oncol; 2015 Apr; 46(4):1481-90. PubMed ID: 25625755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of microRNA-128a in regulating TGFbeta signaling in letrozole-resistant breast cancer cells.
    Masri S; Liu Z; Phung S; Wang E; Yuan YC; Chen S
    Breast Cancer Res Treat; 2010 Nov; 124(1):89-99. PubMed ID: 20054641
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular characterization of aromatase inhibitor-resistant, tamoxifen-resistant and LTEDaro cell lines.
    Masri S; Phung S; Wang X; Chen S
    J Steroid Biochem Mol Biol; 2010 Feb; 118(4-5):277-82. PubMed ID: 19897035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene expression alterations associated with outcome in aromatase inhibitor-treated ER+ early-stage breast cancer patients.
    Thomsen KG; Lyng MB; Elias D; Vever H; Knoop AS; Lykkesfeldt AE; Lænkholm AV; Ditzel HJ
    Breast Cancer Res Treat; 2015 Dec; 154(3):483-94. PubMed ID: 26585578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Growth inhibition of estrogen receptor-positive and aromatase-positive human breast cancer cells in monolayer and spheroid cultures by letrozole, anastrozole, and tamoxifen.
    Kijima I; Itoh T; Chen S
    J Steroid Biochem Mol Biol; 2005 Dec; 97(4):360-8. PubMed ID: 16263272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AIB1:ERα transcriptional activity is selectively enhanced in aromatase inhibitor-resistant breast cancer cells.
    O'Hara J; Vareslija D; McBryan J; Bane F; Tibbitts P; Byrne C; Conroy RM; Hao Y; Gaora PÓ; Hill AD; McIlroy M; Young LS
    Clin Cancer Res; 2012 Jun; 18(12):3305-15. PubMed ID: 22550166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AKT-aro and HER2-aro, models for de novo resistance to aromatase inhibitors; molecular characterization and inhibitor response studies.
    Wong C; Wang X; Smith D; Reddy K; Chen S
    Breast Cancer Res Treat; 2012 Jul; 134(2):671-81. PubMed ID: 22706627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Letrozole-, anastrozole-, and tamoxifen-responsive genes in MCF-7aro cells: a microarray approach.
    Itoh T; Karlsberg K; Kijima I; Yuan YC; Smith D; Ye J; Chen S
    Mol Cancer Res; 2005 Apr; 3(4):203-18. PubMed ID: 15831674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Jagged1 promotes aromatase inhibitor resistance by modulating tumor-associated macrophage differentiation in breast cancer patients.
    Liu H; Wang J; Zhang M; Xuan Q; Wang Z; Lian X; Zhang Q
    Breast Cancer Res Treat; 2017 Nov; 166(1):95-107. PubMed ID: 28730338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. miRNA expression patterns in chemoresistant breast cancer tissues.
    Lv J; Xia K; Xu P; Sun E; Ma J; Gao S; Zhou Q; Zhang M; Wang F; Chen F; Zhou P; Fu Z; Xie H
    Biomed Pharmacother; 2014 Oct; 68(8):935-42. PubMed ID: 25451164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aromatase and breast cancer.
    Brodie A; Sabnis G; Jelovac D
    J Steroid Biochem Mol Biol; 2006 Dec; 102(1-5):97-102. PubMed ID: 17113978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of the K303R estrogen receptor-alpha breast cancer mutation induces resistance to an aromatase inhibitor via addiction to the PI3K/Akt kinase pathway.
    Barone I; Cui Y; Herynk MH; Corona-Rodriguez A; Giordano C; Selever J; Beyer A; Andò S; Fuqua SA
    Cancer Res; 2009 Jun; 69(11):4724-32. PubMed ID: 19487288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and mechanism of action of Proellex, an antiprogestin in aromatase overexpressing and Letrozole resistant T47D breast cancer cells.
    Gupta A; Mehta R; Alimirah F; Peng X; Murillo G; Wiehle R; Mehta RG
    J Steroid Biochem Mol Biol; 2013 Jan; 133():30-42. PubMed ID: 22939887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GP88 (PC-Cell Derived Growth Factor, progranulin) stimulates proliferation and confers letrozole resistance to aromatase overexpressing breast cancer cells.
    Abrhale T; Brodie A; Sabnis G; Macedo L; Tian C; Yue B; Serrero G
    BMC Cancer; 2011 Jun; 11():231. PubMed ID: 21658239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genome-wide analysis of aromatase inhibitor-resistant, tamoxifen-resistant, and long-term estrogen-deprived cells reveals a role for estrogen receptor.
    Masri S; Phung S; Wang X; Wu X; Yuan YC; Wagman L; Chen S
    Cancer Res; 2008 Jun; 68(12):4910-8. PubMed ID: 18559539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 108.